Denali Therapeutics Inc.
DNLI
$15.15
$0.261.75%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | 99.79M | 98.24M | 14.36M | 107.02M | 115.70M |
| Gross Profit | -99.79M | -98.24M | -14.36M | -107.02M | -115.70M |
| SG&A Expenses | 30.06M | 24.95M | 25.19M | 25.24M | 24.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 129.85M | 123.19M | 116.59M | 132.25M | 140.47M |
| Operating Income | -129.85M | -123.19M | -116.59M | -132.25M | -140.47M |
| Income Before Tax | -114.69M | -107.19M | -99.03M | -101.80M | -119.44M |
| Income Tax Expenses | 68.00K | -- | -- | -- | 30.00K |
| Earnings from Continuing Operations | -114.75M | -107.19M | -99.03M | -101.80M | -119.47M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -114.75M | -107.19M | -99.03M | -101.80M | -119.47M |
| EBIT | -129.85M | -123.19M | -116.59M | -132.25M | -140.47M |
| EBITDA | -129.57M | -120.92M | -114.65M | -130.09M | -138.30M |
| EPS Basic | -0.67 | -0.63 | -0.59 | -0.68 | -0.86 |
| Normalized Basic EPS | -0.44 | -0.40 | -0.37 | -0.53 | -0.63 |
| EPS Diluted | -0.67 | -0.63 | -0.59 | -0.68 | -0.86 |
| Normalized Diluted EPS | -0.44 | -0.40 | -0.37 | -0.53 | -0.63 |
| Average Basic Shares Outstanding | 170.09M | 169.46M | 168.83M | 149.40M | 138.25M |
| Average Diluted Shares Outstanding | 170.09M | 169.46M | 168.83M | 149.40M | 138.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
